课题基金 / 基金详情

Genetic modifiers of Duchenne Muscular Dystrophy

Genetic modifiers of Duchenne Muscular Dystrophy
杜氏肌营养不良症的遗传修饰
批准号:
10522759
负责人:
KEVIN M FLANIGAN
金额:
$94.62万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-05-15 至 2027-07-31
关键词:
20 year oldAffectAgeAwardBecker Muscular DystrophyBirthC-terminalCandidate Disease GeneCardiacCardiomyopathiesCessation of lifeClinicalClinical TrialsDNADataDatabasesDeoxyribonucleasesDiagnosisDiseaseDisease ProgressionDuchenne muscular dystrophyDystrophinEngineeringEnrollmentEuropeExonsFamilyFatty acid glycerol estersFibrosisFirst Independent Research Support and Transition AwardsFundingFutureGene MutationGene-ModifiedGenesGeneticGenetic PolymorphismGenomic SegmentGenotypeGoalsGrantHi-CHypersensitivityLinkMagnetic Resonance ImagingMapsMeasuresMedical Care CostsMethodsModelingMolecularMorbidity - disease rateMusMuscleMuscle FibersMuscular DystrophiesMutationMyopathyNatural HistoryNecrosisOpen Reading FramesOutcomeParentsPathway interactionsPatientsPhenotypePrincipal InvestigatorProteinsQuantitative Trait LociRecontactsRecordsResearchResearch PersonnelResourcesSNP arraySNP genotypingSamplingSeveritiesSeverity of illnessSiblingsSignal TransductionSingle Nucleotide PolymorphismSiteSkeletal MuscleTHBS1 geneTestingTherapeutic InterventionThrombospondin 1United States National Institutes of HealthUpdateValidationVariantWalkingWorkcareercohortcoronary fibrosisdata archivedensitydisabilitydystrophinopathyexon skippinggene therapygenome-widegenomic dataheart functionin silicomalemicro-dystrophinnovelnovel strategiesnovel therapeuticsopportunity costpatient stratificationphenotypic datapreservationprogramspromoterpsychologicpulmonary functionsocioeconomicstherapy outcometraitvalidation studies

项目摘要

项目成果

KEVIN M FLANIGAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Duchenne muscular dystrophy (DMD) is a degenerative muscle disorder that affects approximately 1:3500 to 1:5200 live male births caused by mutations in the X-linked DMD gene. DMD gene mutations result in absence of the dystrophin protein in muscle fibers, leading to myofiber necrosis, endomysial fibrosis, and fat replacement. It is a devastating disorder, leading to loss of ambulation by age 12, and historically to death by age 20. The psychological and socioeconomic effects on families are enormous; these include but are not limited to the costs of medical care, opportunity costs for career and work, and the psychological toll taken on parents and siblings. Our long-term goal is to understand which genes modify disease progression and severity of DMD. Confirming a hypothesis derived from a genetic modifier of muscular dystrophies in mice, we have recently used data from patients enrolled in the United Dystrophinopathy Project (UDP) to demonstrate that polymorphisms in the LTBP4 gene influence age at loss of ambulation. Our objective in this project is to identify additional genetic modifiers of skeletal muscle, cardiac, and ventilatory function, and our central hypothesis is that such modifiers can be identified by use of the UDP database, a unique resource that contains detailed phenotypic data and archived DNA samples from over 900 DMD patients. Our specific aims are to 1) update and analyze phenotypic data within the UDP cohort, 2) map modifier traits by high- density single nucleotide polymorphism arrays, and 3) validate newly identified putative genetic modifiers. Validation will engage collaborating networks of investigators in the US and Europe, who have additional natural history cohorts of DMD patients. At the conclusion of these Aims, we will have gained new information about modifier genes associated with the severity and progression of DMD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes
Center of Research Translation in Muscular Dystrophy Therapeutic Development
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies
Administrative Core
海外基金